H.R. 9186: Controlled Substances Act Clarification in Sciences Act of 2026

This bill, known as the Controlled Substances Act Clarification in Sciences Act of 2026, aims to update and clarify certain aspects of the Controlled Substances Act to better reflect current medical knowledge and scientific understanding. The proposed changes include:

Definitions Update

The bill introduces new definitions in the Controlled Substances Act, specifically:

• Accepted medical use: Refers to the usage of a drug or substance that is approved for medical purposes or used in scientific research to enhance the understanding of health conditions or to develop therapies. It also includes the use of substances deemed legitimate in jurisdictions where they are authorized by law.
• Dependence liability: Describes the potential for a drug to cause physical or psychological dependence.
• Physical dependence: Defined as a physiological state that results from the chronic use of a substance, leading to withdrawal symptoms if the substance is suddenly reduced or stopped.
• Psychological dependence: This situation arises when an individual feels compelled to use a drug due to its rewarding effects or cravings, regardless of whether their use is considered abusive.
• Potential for abuse: It indicates the likelihood that a substance will lead to misuse or addiction.
• Misuse: Refers to the improper usage of a drug, either by taking it in a way not intended or not following a healthcare provider's instructions.
• Potential benefits to society: This term relates to the positive impacts a substance may have in terms of medical and scientific advancement or improvements in public health.

Clarification of Scheduling Roles

The bill modifies the existing provisions concerning how drugs are scheduled (classified) under the law. It specifies that the Attorney General should:

• Base decisions on scheduling drugs on the scientific and medical evaluations provided by the Secretary of Health and Human Services.
• Consider both public health and safety when scheduling a substance, ensuring that controls are appropriate to mitigate risks while maintaining access for medical use.

These updates aim to make the scheduling and regulation of substances more aligned with contemporary medical practices and research, ensuring that legitimate medical uses are recognized and protected while addressing public health concerns. This bill reflects a shift towards a more science-based approach in evaluating controlled substances.

Relevant Companies

• None found